Tiragolumab – Talk Bio

Actionable Insights Powered by AI

Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial

5 months ago talkbio0Tagged Keytruda, Malignant neoplasm of lung, Overall Survival, Phase 3 trial, Roche (company), Skyscraper-01, Tecentriq, TIGIT gene, Tiragolumab

Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq

Roche’s TIGIT Drug Tiragolumab Fails Another Phase 3 Lung Cancer Trial

10 months ago talkbio0Tagged Failure (biologic function), Keytruda, Malignant neoplasm of lung, Phase 3 trial, Roche (company), Tecentriq, TIGIT gene, Tiragolumab

Roche, TIGIT, tiragolumab, lung cancer, Phase 3 trial, failure, Keytruda, Tecentriq